Hydracarbazine

Identification

Name
Hydracarbazine
Accession Number
DB09243
Type
Small Molecule
Groups
Experimental
Description

Hydracarbazine is a pyridazine that has found use as an antihypertensive agent [1] It was once marketed in France under the tradename Normatensyl.

Structure
Thumb
Synonyms
Not Available
External IDs
TH-2151
Categories
UNII
6CTK2FB9QM
CAS number
3614-47-9
Weight
Average: 153.145
Monoisotopic: 153.065059865
Chemical Formula
C5H7N5O
InChI Key
WRYZEGZNBYOMLE-UHFFFAOYSA-N
InChI
InChI=1S/C5H7N5O/c6-5(11)3-1-2-4(8-7)10-9-3/h1-2H,7H2,(H2,6,11)(H,8,10)
IUPAC Name
6-hydrazinylpyridazine-3-carboxamide
SMILES
[H]N([H])N([H])C1=NN=C(C=C1)C(=O)N([H])[H]

Pharmacology

Indication

Was used for the treatment of hypertension [1].

Pharmacodynamics

Relaxes vascular smooth muscle [1].

Mechanism of action

Likely acts similarly to hydralazine, a related compound, which interferes with calcium release from the sarcoplasmic reticulum in response to inositol [2].

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Hydracarbazine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Hydracarbazine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Hydracarbazine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Hydracarbazine.Experimental, Illicit
4-MethoxyamphetamineHydracarbazine may increase the hypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Hydracarbazine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineHydracarbazine may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Abediterol.Investigational
AcarboseHydracarbazine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololHydracarbazine may increase the hypotensive activities of Acebutolol.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Hydracarbazine.Experimental
AlbiglutideHydracarbazine may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Hydracarbazine.Approved, Illicit
AliskirenHydracarbazine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Hydracarbazine.Approved, Investigational
AlogliptinHydracarbazine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Hydracarbazine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Hydracarbazine.Illicit
AlprenololHydracarbazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Hydracarbazine.Approved
AmbrisentanHydracarbazine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineHydracarbazine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineHydracarbazine may increase the serotonergic activities of Amitriptyline.Approved
AmitriptylinoxideHydracarbazine may increase the serotonergic activities of Amitriptylinoxide.Approved, Investigational
AmlodipineHydracarbazine may increase the hypotensive activities of Amlodipine.Approved
AmoxapineHydracarbazine may increase the serotonergic activities of Amoxapine.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Hydracarbazine.Approved, Illicit, Investigational
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Hydracarbazine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Arformoterol.Approved, Investigational
AtenololHydracarbazine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineHydracarbazine may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineHydracarbazine may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Bambuterol.Approved, Investigational
BenazeprilHydracarbazine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideHydracarbazine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinHydracarbazine may increase the hypertensive activities of Benmoxin.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Hydracarbazine.Approved, Illicit
BepridilHydracarbazine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Hydracarbazine.Approved, Investigational
BetaxololHydracarbazine may increase the hypotensive activities of Betaxolol.Approved, Investigational
BethanidineHydracarbazine may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Bezafibrate.Approved, Investigational
BietaserpineHydracarbazine may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostHydracarbazine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololHydracarbazine may increase the hypotensive activities of Bisoprolol.Approved
BitolterolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Bitolterol.Withdrawn
BosentanHydracarbazine may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Hydracarbazine may increase the hypotensive activities of BQ-123.Investigational
BretyliumHydracarbazine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe metabolism of Brexpiprazole can be decreased when combined with Hydracarbazine.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Brimonidine.Approved
BrofaromineHydracarbazine may increase the hypertensive activities of Brofaromine.Experimental
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Hydracarbazine.Approved, Investigational
BupranololHydracarbazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Hydracarbazine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Buspirone.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Hydracarbazine.Approved, Illicit, Vet Approved
ButriptylineHydracarbazine may increase the serotonergic activities of Butriptyline.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Hydracarbazine.Approved
CadralazineHydracarbazine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineHydracarbazine may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinHydracarbazine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanHydracarbazine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilHydracarbazine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilHydracarbazine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilHydracarbazine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Hydracarbazine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Hydracarbazine.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Hydracarbazine.Approved, Investigational
CaroxazoneHydracarbazine may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololHydracarbazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolHydracarbazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololHydracarbazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideHydracarbazine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Hydracarbazine.Illicit, Withdrawn
ChlorpropamideHydracarbazine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneHydracarbazine may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineHydracarbazine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilHydracarbazine may increase the hypotensive activities of Cilazapril.Approved
CinitaprideThe metabolism of Cinitapride can be decreased when combined with Hydracarbazine.Approved, Investigational
CirazolineHydracarbazine may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Hydracarbazine.Approved
ClemastineHydracarbazine may increase the anticholinergic activities of Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineHydracarbazine may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClonidineHydracarbazine may increase the hypertensive activities of Clonidine.Approved
CloranololHydracarbazine may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Hydracarbazine.Approved, Illicit
CryptenamineHydracarbazine may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Hydracarbazine.Approved
CyclopenthiazideHydracarbazine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideHydracarbazine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineHydracarbazine may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinHydracarbazine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Hydracarbazine.Investigational
DebrisoquinHydracarbazine may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilHydracarbazine may increase the hypotensive activities of Delapril.Investigational
DeserpidineHydracarbazine may increase the hypotensive activities of Deserpidine.Approved
DesipramineHydracarbazine may increase the serotonergic activities of Desipramine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Hydracarbazine.Approved, Investigational
DeutetrabenazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Deutetrabenazine.Approved, Investigational
DexmethylphenidateHydracarbazine may increase the hypertensive activities of Dexmethylphenidate.Approved, Investigational
DextroamphetamineThe risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Hydracarbazine.Approved, Illicit
DextromethorphanHydracarbazine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Hydracarbazine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hydracarbazine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Hydracarbazine.Approved, Investigational
DiazoxideHydracarbazine may increase the hypotensive activities of Diazoxide.Approved
DibenzepinHydracarbazine may increase the serotonergic activities of Dibenzepin.Experimental
DiethylnorspermineHydracarbazine may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylpropionHydracarbazine may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineHydracarbazine may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Hydracarbazine.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Hydracarbazine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Hydracarbazine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Hydracarbazine.Experimental, Illicit
DiltiazemHydracarbazine may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimetacrineHydracarbazine may increase the serotonergic activities of Dimetacrine.Approved, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hydracarbazine.Approved, Illicit
DipivefrinHydracarbazine may increase the hypertensive activities of Dipivefrin.Approved
DisopyramideHydracarbazine may increase the hypoglycemic activities of Disopyramide.Approved
DisulfiramThe risk or severity of convulsion can be increased when Hydracarbazine is combined with Disulfiram.Approved
DobutamineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideHydracarbazine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinHydracarbazine may increase the serotonergic activities of Dosulepin.Approved
DoxapramHydracarbazine may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinHydracarbazine may increase the hypotensive activities of Doxazosin.Approved
DoxepinHydracarbazine may increase the serotonergic activities of Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Doxofylline.Approved, Investigational
DoxylamineHydracarbazine may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Hydracarbazine.Experimental
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Hydracarbazine.Experimental, Illicit
DroxidopaHydracarbazine may increase the hypertensive activities of Droxidopa.Approved, Investigational
DulaglutideHydracarbazine may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Hydracarbazine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Hydracarbazine.Experimental, Illicit
EfonidipineHydracarbazine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Hydracarbazine.Approved, Investigational
EmpagliflozinHydracarbazine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilHydracarbazine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatHydracarbazine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineHydracarbazine may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Hydracarbazine.Approved, Investigational
EpanololHydracarbazine may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineHydracarbazine may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolHydracarbazine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanHydracarbazine may increase the hypotensive activities of Eprosartan.Approved
ErgonovineHydracarbazine may increase the hypertensive activities of Ergonovine.Approved
ErgotamineHydracarbazine may increase the hypertensive activities of Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Hydracarbazine.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Etafedrine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Hydracarbazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Hydracarbazine.Approved, Illicit
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Hydracarbazine.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Hydracarbazine.Illicit, Vet Approved
ExenatideHydracarbazine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineHydracarbazine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineHydracarbazine may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoldopamHydracarbazine may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hydracarbazine.Approved, Illicit, Investigational, Vet Approved
Ferulic acidHydracarbazine may increase the hypotensive activities of Ferulic acid.Experimental
FlibanserinThe metabolism of Flibanserin can be decreased when combined with Hydracarbazine.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Hydracarbazine.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Hydracarbazine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Formoterol.Approved, Investigational
FosinoprilHydracarbazine may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Hydracarbazine.Approved, Investigational
FurazolidoneHydracarbazine may increase the hypertensive activities of Furazolidone.Approved, Investigational, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Hydracarbazine.Experimental
GliclazideHydracarbazine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideHydracarbazine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideHydracarbazine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideHydracarbazine may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzHydracarbazine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelHydracarbazine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineHydracarbazine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineHydracarbazine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineHydracarbazine may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorHydracarbazine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzHydracarbazine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanHydracarbazine may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHydracarbazine may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Hydracarbazine.Approved, Illicit, Investigational
HexamethoniumHydracarbazine may increase the hypotensive activities of Hexamethonium.Experimental
HexoprenalineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Hexoprenaline.Approved, Withdrawn
HydralazineHydracarbazine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideHydracarbazine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hydracarbazine.Approved, Illicit
HydroflumethiazideHydracarbazine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydracarbazine.Approved, Illicit
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Hydracarbazine.Approved
ImidaprilHydracarbazine may increase the hypotensive activities of Imidapril.Investigational
ImipramineHydracarbazine may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Indalpine is combined with Hydracarbazine.Investigational, Withdrawn
IndapamideHydracarbazine may increase the hypotensive activities of Indapamide.Approved
IndenololHydracarbazine may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminHydracarbazine may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartHydracarbazine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirHydracarbazine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineHydracarbazine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineHydracarbazine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanHydracarbazine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproHydracarbazine may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Hydracarbazine.Approved
IprindoleHydracarbazine may increase the serotonergic activities of Iprindole.Experimental
IproclozideHydracarbazine may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Hydracarbazine.Withdrawn
IrbesartanHydracarbazine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Hydracarbazine.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Isoprenaline.Approved, Investigational
IsradipineHydracarbazine may increase the hypotensive activities of Isradipine.Approved, Investigational
KetanserinHydracarbazine may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Hydracarbazine.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Hydracarbazine.Approved, Nutraceutical, Withdrawn
LabetalolHydracarbazine may increase the hypotensive activities of Labetalol.Approved
LacidipineHydracarbazine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostHydracarbazine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineHydracarbazine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Hydracarbazine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Hydracarbazine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Hydracarbazine.Approved, Investigational
LevonordefrinHydracarbazine may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hydracarbazine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Levosalbutamol.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Linezolid.Approved, Investigational
LinsidomineHydracarbazine may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideHydracarbazine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Hydracarbazine.Approved, Investigational
LisinoprilHydracarbazine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Hydracarbazine.Approved, Investigational
Lithium cationThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Lithium.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Hydracarbazine.Illicit
LofepramineHydracarbazine may increase the serotonergic activities of Lofepramine.Experimental
LofexidineThe metabolism of Lofexidine can be decreased when combined with Hydracarbazine.Approved, Investigational
LorpiprazoleThe risk or severity of serotonin syndrome can be increased when Lorpiprazole is combined with Hydracarbazine.Approved
LosartanHydracarbazine may increase the hypotensive activities of Losartan.Approved
MacitentanHydracarbazine may increase the hypotensive activities of Macitentan.Approved
ManidipineHydracarbazine may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Maprotiline.Approved, Investigational
MebanazineHydracarbazine may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineHydracarbazine may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MecaserminHydracarbazine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MelitracenHydracarbazine may increase the serotonergic activities of Melitracen.Experimental, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Mephedrone is combined with Hydracarbazine.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Hydracarbazine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Hydracarbazine.Experimental
MequitazineHydracarbazine may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolHydracarbazine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminHydracarbazine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Hydracarbazine.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Hydracarbazine.Approved, Illicit
MethoserpidineHydracarbazine may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineHydracarbazine may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Hydracarbazine.Experimental
MethyldopaThe risk or severity of hypertension can be increased when Hydracarbazine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Hydracarbazine.Experimental
Methylene blueHydracarbazine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateHydracarbazine may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethysergideThe metabolism of Methysergide can be decreased when combined with Hydracarbazine.Approved
MetipranololHydracarbazine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneHydracarbazine may increase the hypotensive activities of Metolazone.Approved
MetoprololHydracarbazine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineHydracarbazine may increase the hypotensive activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Mianserin.Approved, Investigational
MibefradilHydracarbazine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineHydracarbazine may increase the hypertensive activities of Midodrine.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Hydracarbazine.Experimental, Illicit, Investigational
MifepristoneHydracarbazine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolHydracarbazine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Hydracarbazine.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Hydracarbazine.Approved
MinoxidilHydracarbazine may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Mirtazapine.Approved
MMDAThe risk or severity of adverse effects can be increased when MMDA is combined with Hydracarbazine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Moclobemide.Approved, Investigational
MoexiprilHydracarbazine may increase the hypotensive activities of Moexipril.Approved
MorphineThe therapeutic efficacy of Morphine can be increased when used in combination with Hydracarbazine.Approved, Investigational
MoxonidineHydracarbazine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineHydracarbazine may increase the hypotensive activities of Muzolimine.Experimental
NadololHydracarbazine may increase the hypotensive activities of Nadolol.Approved
NaftopidilHydracarbazine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Hydracarbazine.Approved
NaluzotanThe metabolism of Naluzotan can be decreased when combined with Hydracarbazine.Investigational
NaphazolineHydracarbazine may increase the hypertensive activities of Naphazoline.Approved
NaratriptanThe serum concentration of Naratriptan can be increased when it is combined with Hydracarbazine.Approved, Investigational
NateglinideHydracarbazine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololHydracarbazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Hydracarbazine.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Hydracarbazine.Withdrawn
NicardipineHydracarbazine may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilHydracarbazine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineHydracarbazine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineHydracarbazine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineHydracarbazine may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineHydracarbazine may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineHydracarbazine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideHydracarbazine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NorepinephrineHydracarbazine may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Hydracarbazine.Approved, Illicit
NortriptylineHydracarbazine may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinHydracarbazine may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineHydracarbazine may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlmesartanHydracarbazine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Olodaterol.Approved
OmapatrilatHydracarbazine may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolHydracarbazine may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Hydracarbazine.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Orciprenaline.Approved
OxprenololHydracarbazine may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Oxycodone.Approved, Illicit, Investigational
OxymetazolineHydracarbazine may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hydracarbazine.Approved, Investigational, Vet Approved
PargylinePargyline may increase the hypertensive activities of Hydracarbazine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Hydracarbazine.Approved, Investigational
PenbutololHydracarbazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineHydracarbazine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hydracarbazine.Approved, Vet Approved
PentoliniumHydracarbazine may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Hydracarbazine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilHydracarbazine may increase the hypotensive activities of Perindopril.Approved
PethidineHydracarbazine may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Hydracarbazine is combined with PF-00610355.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Hydracarbazine.Experimental
PhendimetrazineHydracarbazine may increase the hypertensive activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypertensive activities of Hydracarbazine.Approved
PheniprazineHydracarbazine may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Hydracarbazine.Experimental
PhenoxybenzamineHydracarbazine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineHydracarbazine may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Hydracarbazine.Approved, Illicit
PhentolamineHydracarbazine may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineHydracarbazine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Hydracarbazine.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Hydracarbazine.Investigational
PinacidilHydracarbazine may increase the hypotensive activities of Pinacidil.Approved
PindololHydracarbazine may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneHydracarbazine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Hydracarbazine.Approved, Investigational
PirlindolePirlindole may increase the hypertensive activities of Hydracarbazine.Approved
PivhydrazineHydracarbazine may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenHydracarbazine may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorHydracarbazine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideHydracarbazine may increase the hypotensive activities of Polythiazide.Approved
PramlintideHydracarbazine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinHydracarbazine may increase the hypotensive activities of Prazosin.Approved
ProcaineHydracarbazine may increase the hypertensive activities of Procaine.Approved, Investigational, Vet Approved
ProcarbazineHydracarbazine may increase the hypertensive activities of Procarbazine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Procaterol.Approved, Investigational
PropranololHydracarbazine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Protokylol.Approved, Vet Approved
ProtriptylineHydracarbazine may increase the serotonergic activities of Protriptyline.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Hydracarbazine.Approved
QuinaprilHydracarbazine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineHydracarbazine may increase the hypoglycemic activities of Quinine.Approved
RacepinephrineHydracarbazine may increase the hypertensive activities of Racepinephrine.Approved
RamiprilHydracarbazine may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Hydracarbazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydracarbazine.Approved
RemikirenHydracarbazine may increase the hypotensive activities of Remikiren.Approved
RepaglinideHydracarbazine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineHydracarbazine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Reserpine.Approved, Investigational
RilmenidineHydracarbazine may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RiociguatHydracarbazine may increase the hypotensive activities of Riociguat.Approved
RitobegronThe risk or severity of adverse effects can be increased when Ritobegron is combined with Hydracarbazine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Ritodrine.Approved, Investigational
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Hydracarbazine.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Hydracarbazine.Approved, Investigational
RosiglitazoneHydracarbazine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe metabolism of Rotigotine can be decreased when combined with Hydracarbazine.Approved
SafrazineHydracarbazine may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Salmeterol.Approved
SaprisartanHydracarbazine may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinHydracarbazine may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Hydracarbazine.Approved, Investigational, Vet Approved
SelexipagHydracarbazine may increase the hypotensive activities of Selexipag.Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Hydracarbazine.Approved
SitagliptinHydracarbazine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanHydracarbazine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilHydracarbazine may increase the hypotensive activities of Spirapril.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydracarbazine.Approved, Investigational
SulfadiazineHydracarbazine may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleHydracarbazine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleHydracarbazine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Hydracarbazine.Approved, Investigational
SunitinibHydracarbazine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololHydracarbazine may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Hydracarbazine.Approved
TelmisartanHydracarbazine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilHydracarbazine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Terbutaline.Approved
TerlipressinHydracarbazine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Tetrabenazine.Approved, Investigational
TetrahydrocannabivarinThe metabolism of Tetrahydrocannabivarin can be decreased when combined with Hydracarbazine.Investigational
TetrahydropalmatineHydracarbazine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineHydracarbazine may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineHydracarbazine may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Hydracarbazine.Approved, Investigational
TiboloneHydracarbazine may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenHydracarbazine may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Hydracarbazine.Experimental
TimololHydracarbazine may increase the hypotensive activities of Timolol.Approved
TolazamideHydracarbazine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineHydracarbazine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideHydracarbazine may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Hydracarbazine.Approved, Withdrawn
TolonidineHydracarbazine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Hydracarbazine.Approved
TorasemideHydracarbazine may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Hydracarbazine.Approved, Investigational
TrandolaprilHydracarbazine may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypertensive activities of Hydracarbazine.Approved, Investigational
TravoprostHydracarbazine may increase the hypotensive activities of Travoprost.Approved
TrazodoneHydracarbazine may increase the serotonergic activities of Trazodone.Approved, Investigational
TreprostinilHydracarbazine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideHydracarbazine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinHydracarbazine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanHydracarbazine may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineHydracarbazine may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneHydracarbazine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilHydracarbazine may increase the hypotensive activities of Urapidil.Investigational
ValsartanHydracarbazine may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Hydracarbazine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Hydracarbazine.Approved
VincamineHydracarbazine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineHydracarbazine may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Hydracarbazine.Approved, Investigational
XipamideHydracarbazine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineHydracarbazine may increase the hypertensive activities of Xylometazoline.Approved, Investigational
ZimelidineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Hydracarbazine.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Hydracarbazine.Approved
ZofenoprilHydracarbazine may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Hydracarbazine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Francis JE: Antihypertensives acting by a peripheral mechanism ACS Symposium Series. 1976 June 01;27:55-79.
  2. 22. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 273). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
External Links
PubChem Compound
71653
PubChem Substance
310265146
ChemSpider
64713
ChEBI
136055
ChEMBL
CHEMBL2106246
Wikipedia
Hydracarbazine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility9.3 mg/mLALOGPS
logP-0.95ALOGPS
logP-1ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)13.88ChemAxon
pKa (Strongest Basic)6.03ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area106.92 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity42.49 m3·mol-1ChemAxon
Polarizability14.15 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 2-heteroaryl carboxamides. These are compounds containing a heteroaromatic ring that carries a carboxamide group.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Carboxylic acid derivatives
Direct Parent
2-heteroaryl carboxamides
Alternative Parents
Pyridazines and derivatives / Imidolactams / Heteroaromatic compounds / Primary carboxylic acid amides / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives / Hydrazines and derivatives
Substituents
2-heteroaryl carboxamide / Pyridazine / Imidolactam / Heteroaromatic compound / Primary carboxylic acid amide / Organoheterocyclic compound / Azacycle / Hydrazine derivative / Organopnictogen compound / Organic oxygen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 16:06 / Updated on July 02, 2018 19:13